On May 17, 2024 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, reported upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver (Press release, Chemomab, MAY 17, 2024, View Source [SID1234643423]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations cover a range of topics, from new preclinical studies further elucidating the roles of the soluble protein target CCL24 and Chemomab’s CCL24 neutralizing antibody CM-101 in fibro-inflammatory disease, to novel translational research designed to support the ongoing clinical development of CM-101 for primary sclerosing cholangitis, a rare and often fatal fibrotic liver disease. The presentations will be made available and described in greater detail post embargo.
Gordon Research Conference: Chemotactic Cytokines – Portland, Maine, USA, June 2-7, 2024
Date: June 2-7, 2024
Format: Poster presentation: Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes and neutrophils and modulates hepatic stellate cell activation
Presenter: Prof. Amnon Peled, Hadassah University Hospital; Faculty of Medicine, Hebrew University
Information: 2024 Chemotactic Cytokines Conference GRC
EASL Congress 2024 – Milan, Italy, June 5-8, 2024
Date: June 6, 2024
Time: 8:30-18:00 CEST
Format: Poster presentation: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter: Revital Aricha, PhD, Vice President, Translational Science, Chemomab Therapeutics
Session: Poster – Fibrosis/Stellate cell biology, Abstract #380
Date: June 6, 2024
Time: 8:30-17:00 CEST
Format: Poster presentation: Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score
Presenter: Ilan Vaknin, PhD, Vice President, R&D, Chemomab Therapeutics
Session: Immune-mediated and cholestatic: Experimental and pathophysiology, Abstract #1032
Date: June 7, 2024
Time: 12:25-13:45 CEST
Format: Poster Tour: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter: Ilan Vaknin, PhD, Vice President, R&D, Chemomab Therapeutics
Session: Fibrosis/Stellate Cell Biology Poster Tour, Abstract #380
Location: Basic Science Track Hub
Information: EASL Congress 2024
In addition, Chemomab Corporate Development will be in San Diego June 3-6, 2024, participating in the BIO International Convention’s One-on-One Partnering event. Registered attendees can click here to log in and schedule a meeting with Chemomab.